(Q46656221)

24 December 2017

title

Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo (English)

1 reference

24 December 2017

author name string

Yuka Someya

1

1 reference

24 December 2017

Atsuo Tahara

2

1 reference

24 December 2017

Ryosuke Nakano

3

1 reference

24 December 2017

Akiko Matsuyama-Yokono

4

1 reference

24 December 2017

Itsuro Nagase

5

1 reference

24 December 2017

Yasuhisa Fukunaga

6

1 reference

24 December 2017

Toshiyuki Takasu

7

1 reference

24 December 2017

Masahiko Hayakawa

8

1 reference

24 December 2017

Masayuki Shibasaki

9

1 reference

24 December 2017

publication date

9 April 2008

1 reference

24 December 2017

Naunyn-Schmiedeberg's Archives of Pharmacology

published in

1 reference

24 December 2017

volume

377

1 reference

24 December 2017

issue

3

1 reference

24 December 2017

page(s)

209-217

1 reference

24 December 2017

https://scigraph.springernature.com/pub.10.1007/s00210-008-0277-8

exact match

0 references

cites work

Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00210-008-0277-8

Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM?

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00210-008-0277-8

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV

21 January 2018

1 reference

12 December 2020

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

1 reference

12 December 2020

The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion

1 reference

12 December 2020

Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII

1 reference

12 December 2020

Pancreatic and extrapancreatic sulfonylurea receptors

1 reference

12 December 2020

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

1 reference

12 December 2020

Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

1 reference

12 December 2020

K579, a slow-binding inhibitor of dipeptidyl peptidase IV, is a long-acting hypoglycemic agent

1 reference

12 December 2020

Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats

1 reference

12 December 2020

Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

1 reference

12 December 2020

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

1 reference

12 December 2020

Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8

1 reference

12 December 2020

Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV

1 reference

12 December 2020

Sequence, purification, and cloning of an intracellular serine protease, quiescent cell proline dipeptidase

1 reference

12 December 2020

Higher incidence of severe hypoglycaemia leading to hospital admission in Type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas

1 reference

12 December 2020

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

1 reference

12 December 2020

Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus

1 reference

12 December 2020

Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response

1 reference

12 December 2020

Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.

1 reference

12 December 2020

Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes.

1 reference

12 December 2020

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

1 reference

12 December 2020

Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats

1 reference

12 December 2020

Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts

1 reference

12 December 2020

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

1 reference

12 December 2020

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

1 reference

12 December 2020

10.1007/S00210-008-0277-8

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017